clofibrate trial summary

No demonstrated result

suggested Coronary event by 13% (not demonstrated)

suggested Coronary death by 14% (not demonstrated)

suggested Non fatal MI by 18% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	1.78 [1.07 2.95]	p=0.04	0	3892	1	CDP Clofibrate,
cardiovascular events	1.35 [0.83 2.21]	p=1.00	0	532	1	VA Neurology Section,
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.87 [0.78 0.97]	p=0.04	0	17026	6	WHO clofibrate,CDP Clofibrate,Scottish,Newcastle,VA Neurology Section,Hanefeld,
Coronary death and non fatal MI	no data
Coronary death	0.86 [0.74 0.99]	p=0.04	0	16523	8	WHO clofibrate,CDP Clofibrate,Scottish,Newcastle,Harrold,Begg,VA Neurology Section,Cullen,
cardiac death	0.87 [0.75 1.00]	p=1.00	0	16523	8	WHO clofibrate,CDP Clofibrate,Scottish,Newcastle,Harrold,Begg,VA Neurology Section,Cullen,
MACE	no data
Non fatal MI	0.82 [0.71 0.94]	p=0.04	0	15733	4	WHO clofibrate,CDP Clofibrate,Scottish,Newcastle,
All cause death	1.00 [0.89 1.12]	p=1.00	0	16618	9	WHO clofibrate,CDP Clofibrate,Scottish,Newcastle,Harrold,Begg,Acheson,VA Neurology Section,Cullen,
non cardiovascular death	1.42 [1.18 1.72]	p=0.04	0	15733	4	WHO clofibrate,CDP Clofibrate,Scottish,Newcastle,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	1.29 [0.94 1.78]	p=1.00	0	14519	2	WHO clofibrate,CDP Clofibrate,
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	no data
Coronary death and non fatal MI	no data
Coronary death	1.02 [0.02 52.51]	p=1.00	0	97	1	SCOR,
cardiac death	no data
MACE	no data
Non fatal MI	no data
All cause death	0.34 [0.01 8.57]	p=1.00	0	97	1	SCOR,
non cardiovascular death	0.34 [0.01 8.57]	p=1.00	0	97	1	SCOR,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

suggested Coronary event by 13% (not demonstrated)

suggested Coronary death by 14% (not demonstrated)

suggested Non fatal MI by 18% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	1.78 [1.07 2.95]	p=0.04	0	3892	1	CDP Clofibrate,
cardiovascular events	1.35 [0.83 2.21]	p=1.00	0	532	1	VA Neurology Section,
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.87 [0.78 0.97]	p=0.04	0	17026	6	WHO clofibrate,CDP Clofibrate,Scottish,Newcastle,VA Neurology Section,Hanefeld,
Coronary death and non fatal MI	no data
Coronary death	0.86 [0.74 0.99]	p=0.04	0	16523	8	WHO clofibrate,CDP Clofibrate,Scottish,Newcastle,Harrold,Begg,VA Neurology Section,Cullen,
cardiac death	0.87 [0.75 1.00]	p=1.00	0	16523	8	WHO clofibrate,CDP Clofibrate,Scottish,Newcastle,Harrold,Begg,VA Neurology Section,Cullen,
MACE	no data
Non fatal MI	0.82 [0.71 0.94]	p=0.04	0	15733	4	WHO clofibrate,CDP Clofibrate,Scottish,Newcastle,
All cause death	1.00 [0.89 1.12]	p=1.00	0	16618	9	WHO clofibrate,CDP Clofibrate,Scottish,Newcastle,Harrold,Begg,Acheson,VA Neurology Section,Cullen,
non cardiovascular death	1.42 [1.18 1.72]	p=0.04	0	15733	4	WHO clofibrate,CDP Clofibrate,Scottish,Newcastle,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	1.29 [0.94 1.78]	p=1.00	0	14519	2	WHO clofibrate,CDP Clofibrate,
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Diabetic patients : 2 trials - Harrold - Hanefeld

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	1.04 [0.62 1.74]	p=1.00	0	761	1	Hanefeld,
Coronary death and non fatal MI	no data
Coronary death	0.22 [0.01 4.78]	p=1.00	0	63	1	Harrold,
cardiac death	0.22 [0.01 4.78]	p=1.00	0	63	1	Harrold,
MACE	no data
Non fatal MI	no data
All cause death	0.16 [0.01 3.18]	p=1.00	0	63	1	Harrold,
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with LDL elevation and without CHD: 2 trials - WHO clofibrate - Cullen

No demonstrated result

suggested Non fatal MI by 25% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	no data
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.83 [0.68 1.01]	p=1.00	0	10627	1	WHO clofibrate,
Coronary death and non fatal MI	no data
Coronary death	1.10 [0.75 1.62]	p=1.00	0	10667	2	WHO clofibrate,Cullen,
cardiac death	1.10 [0.75 1.62]	p=1.00	0	10667	2	WHO clofibrate,Cullen,
MACE	no data
Non fatal MI	0.75 [0.59 0.94]	p=0.04	0	10627	1	WHO clofibrate,
All cause death	1.26 [0.99 1.59]	p=1.00	0	10667	2	WHO clofibrate,Cullen,
non cardiovascular death	1.41 [1.07 1.86]	p=0.04	0	10627	1	WHO clofibrate,
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	1.35 [0.95 1.92]	p=1.00	0	10627	1	WHO clofibrate,
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with other atherosclerotic localisation: 3 trials - Begg - Acheson - VA Neurology Section

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	no data
cardiovascular events	1.35 [0.83 2.21]	p=1.00	0	532	1	VA Neurology Section,
Cardiovascular death	no data
stroke (fatal and non fatal)	no data
Coronary event	0.88 [0.33 2.31]	p=1.00	0	532	1	VA Neurology Section,
Coronary death and non fatal MI	no data
Coronary death	0.73 [0.37 1.45]	p=1.00	0	687	2	Begg,VA Neurology Section,
cardiac death	0.91 [0.40 2.06]	p=1.00	0	687	2	Begg,VA Neurology Section,
MACE	no data
Non fatal MI	no data
All cause death	0.77 [0.50 1.20]	p=1.00	0	782	3	Begg,Acheson,VA Neurology Section,
non cardiovascular death	no data
Fatal stroke	no data
Haemmorhagic stroke	no data
new-onset diabetes	no data
Death from cancer	no data
Rhabdomyolysis	no data
Myopathy	no data
Cancer	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Clofibrate cholesterol lowering intervention